Joseph Piepmeier, MD, FAANS
DownloadHi-Res Photo
Cards
Appointments
Neurosurgery
Primary
Contact Info
Neurosurgery
PO Box 208082
New Haven, CT 06520-8082
United States
About
Titles
Nixdorff-German Professor Emeritus of Neurosurgery
Biography
Dr. Joseph M. Piepmeier serves as the Chief of the Section of Surgical Neuro-oncology and Vice-Chair for Clinical Affairs in the Department of Neurosurgery. He received his undergraduate degree from Duke University and his M.D. from the University of Tennessee School of Medicine. He completed his internship and residency training in neurosurgery at Yale University School of Medicine and joined the neurosurgery faculty in 1982. He is certified by the American Board of Neurological Surgery. The primary focus of Dr. Piepmeier's clinical and laboratory work is neuro-oncology.
Appointments
Neurosurgery
EmeritusPrimary
Other Departments & Organizations
- Brain Tumor Center
- Developmental Therapeutics
- Gamma Knife Center
- Gamma Knife Radiosurgery
- Neurosurgery
- Yale Cancer Center
Education & Training
- MD
- University of Tennessee (1975)
- Resident
- Yale-New Haven Hospital
- Fellow
- Yale-New Haven Hospital
Board Certifications
Neurological Surgery
- Certification Organization
- AB of Neurological Surgery
- Original Certification Date
- 1984
Research
Overview
Medical Subject Headings (MeSH)
Biopsy, Needle; Brain Neoplasms; Diseases; Neoplasms; Nervous System Diseases; Neuroma, Acoustic; Neurosurgery
Research at a Glance
Yale Co-Authors
Frequent collaborators of Joseph Piepmeier's published research.
Publications Timeline
A big-picture view of Joseph Piepmeier's research output by year.
Research Interests
Research topics Joseph Piepmeier is interested in exploring.
Anita Huttner, MD
Michael B. Bracken, PhD, MPH, FACE
Theodore Holford, PhD
Jiangbing Zhou, PhD
Murat Gunel, MD, FACS, FAHA, FAANS
Robert Makuch, PhD
115Publications
10,515Citations
Brain Neoplasms
Neoplasms
Neurosurgery
Publications
2020
Primary melanotic tumors of the nervous system: a consecutive case series
Grosshans H, Huttner A, Piepmeier J, Kaulen L, Fulbright R, Baehring J, Karschnia P. Primary melanotic tumors of the nervous system: a consecutive case series. European Journal Of Neurology 2020, 27: 2303-2307. PMID: 32654331, DOI: 10.1111/ene.14437.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsPrimary melanotic tumorsNervous systemRelapsed diseaseClinical presentationMelanotic lesionsFavorable outcomeRadiation therapyPre-contrast T1-weighted imagingRelative incidenceMelanotic tumorsHomogenous contrast enhancementYale Cancer CenterAggressive surgical treatmentConsecutive case seriesPsammomatous melanotic schwannomaNervous system tumorsT1-weighted imagingT2-weighted imagingTumor mass effectMagnetic resonance imagingMelanin-containing cellsS100 positivitySurgical resectionSurgical treatmentTumor Registry
2019
Leptomeningeal dissemination of low-grade neuroepithelial CNS tumors in adults: a 15-year experience
Karschnia P, Barbiero FJ, Schwaiblmair MH, Kaulen LD, Piepmeier JM, Huttner AJ, Becker KP, Fulbright RK, Baehring JM. Leptomeningeal dissemination of low-grade neuroepithelial CNS tumors in adults: a 15-year experience. Neuro-Oncology Practice 2019, 7: 118-126. PMID: 32257290, PMCID: PMC7104875, DOI: 10.1093/nop/npz020.Peer-Reviewed Original ResearchCitationsConceptsLeptomeningeal disseminationRare complicationCNS tumorsInitial tumor diagnosisMedian overall survivalYale Cancer CenterPredictors of outcomeMean time intervalAggressive treatmentOverall survivalSystemic therapyConsecutive patientsSystemic treatmentTumor depositsClinical presentationCancer CenterHistopathological diagnosisHistological entityClinical signsTimely diagnosisNeuro-oncologyTumor spectrumEarly symptomsVariable enhancementRelative incidence
2018
Mibefradil dihydrochoride with hypofractionated radiation for recurrent glioblastoma: A phase I dose expansion trial.
Lester-Coll N, Supko J, Kluytenaar J, Pavlik K, Yu J, Moliterno J, Piepmeier J, Becker K, Baehring J, Huttner A, Vortmeyer A, Contessa J, Ramani R, Lampert R, Yao X, Bindra R. Mibefradil dihydrochoride with hypofractionated radiation for recurrent glioblastoma: A phase I dose expansion trial. Journal Of Clinical Oncology 2018, 36: e14046-e14046. DOI: 10.1200/jco.2018.36.15_suppl.e14046.Peer-Reviewed Original ResearchCitationsLeptomeningeal dissemination from low-grade neuroepithelial CNS tumors in adults: a 15-year experience (P6.159)
Karschnia P, Barbiero F, Schwaiblmair M, Piepmeier J, Huttner A, Becker K, Fulbright R, Baehring J. Leptomeningeal dissemination from low-grade neuroepithelial CNS tumors in adults: a 15-year experience (P6.159). Neurology 2018, 90 DOI: 10.1212/wnl.90.15_supplement.p6.159.Peer-Reviewed Original Research
2016
Mibefradil Dihydrochloride With Hypofractionated Radiation for Recurrent Glioblastoma: Preliminary Results of a Phase 1 Dose Expansion Trial
Lester-Coll N, Kluytenaar J, Pavlik K, Yu J, Contessa J, Moliterno J, Piepmeier J, Becker K, Baehring J, Huttner A, Vortmeyer A, Ramani R, Lampert R, Yao X, Bindra R. Mibefradil Dihydrochloride With Hypofractionated Radiation for Recurrent Glioblastoma: Preliminary Results of a Phase 1 Dose Expansion Trial. International Journal Of Radiation Oncology • Biology • Physics 2016, 96: s93. DOI: 10.1016/j.ijrobp.2016.06.233.Peer-Reviewed Original ResearchCitationsRecurrent somatic mutations in POLR2A define a distinct subset of meningiomas
Clark VE, Harmancı AS, Bai H, Youngblood MW, Lee TI, Baranoski JF, Ercan-Sencicek AG, Abraham BJ, Weintraub AS, Hnisz D, Simon M, Krischek B, Erson-Omay EZ, Henegariu O, Carrión-Grant G, Mishra-Gorur K, Durán D, Goldmann JE, Schramm J, Goldbrunner R, Piepmeier JM, Vortmeyer AO, Günel JM, Bilgüvar K, Yasuno K, Young RA, Günel M. Recurrent somatic mutations in POLR2A define a distinct subset of meningiomas. Nature Genetics 2016, 48: 1253-1259. PMID: 27548314, PMCID: PMC5114141, DOI: 10.1038/ng.3651.Peer-Reviewed Original ResearchCitationsAltmetricMeSH KeywordsCatalytic DomainChromosomes, Human, Pair 22Cohort StudiesDNA Mutational AnalysisEnhancer Elements, GeneticExomeGene Expression Regulation, NeoplasticGenotypeHumansKruppel-Like Factor 4Kruppel-Like Transcription FactorsMeningeal NeoplasmsMeningiomaMutationNeurofibromin 2RNA Polymerase IITumor Necrosis Factor Receptor-Associated Peptides and ProteinsIncreased Nanoparticle Delivery to Brain Tumors by Autocatalytic Priming for Improved Treatment and Imaging
Han L, Kong DK, Zheng MQ, Murikinati S, Ma C, Yuan P, Li L, Tian D, Cai Q, Ye C, Holden D, Park JH, Gao X, Thomas JL, Grutzendler J, Carson RE, Huang Y, Piepmeier JM, Zhou J. Increased Nanoparticle Delivery to Brain Tumors by Autocatalytic Priming for Improved Treatment and Imaging. ACS Nano 2016, 10: 4209-4218. PMID: 26967254, PMCID: PMC5257033, DOI: 10.1021/acsnano.5b07573.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsMeSH KeywordsAnimalsAntineoplastic AgentsBiological TransportBlood-Brain BarrierBrain NeoplasmsCell Line, TumorDecanoic AcidsDrug Delivery SystemsEthanolaminesFemaleGenetic TherapyHeterograftsHumansMatrix Metalloproteinase 2MiceMice, Inbred C57BLNanoparticlesOptical ImagingPaclitaxelPermeabilityPolymersPurinesPyrazolesScorpion VenomsTranscytosisTumor MicroenvironmentConceptsBlood-brain barrierLow delivery efficiencyTransport of nanoparticlesCancer gene therapyNanoparticle deliveryMore nanoparticlesBrain tumorsNanoparticlesDelivery efficiencyGene therapySystemic deliveryNPsBrain malignanciesBBB modulatorsPharmacological agentsBrain cancerBrain regionsTumorsDeliveryBrainImproved treatmentInadequate amountsPositive feedback loopChemotherapyMalignancy
2015
ATNT-15MIBEFRADIL DIHYDROCHORIDE WITH HYPOFRACTIONATED RADIATION FOR RECURRENT GLIOBLASTOMA: PRELIMINARY RESULTS OF A PHASE I DOSE EXPANSION TRIAL
Lester-Coll N, Kluytenaar J, Pavlik K, Yu J, Contessa J, Moliterno J, Piepmeier J, Becker K, Baehring J, Huttner A, Vortmeyer A, Ramani R, Lampert R, Yao X, Bindra R. ATNT-15MIBEFRADIL DIHYDROCHORIDE WITH HYPOFRACTIONATED RADIATION FOR RECURRENT GLIOBLASTOMA: PRELIMINARY RESULTS OF A PHASE I DOSE EXPANSION TRIAL. Neuro-Oncology 2015, 17: v13-v13. PMCID: PMC4638537, DOI: 10.1093/neuonc/nov205.15.Peer-Reviewed Original ResearchCitations
2014
Imaging the delivery of brain-penetrating PLGA nanoparticles in the brain using magnetic resonance
Strohbehn G, Coman D, Han L, Ragheb RR, Fahmy TM, Huttner AJ, Hyder F, Piepmeier JM, Saltzman WM, Zhou J. Imaging the delivery of brain-penetrating PLGA nanoparticles in the brain using magnetic resonance. Journal Of Neuro-Oncology 2014, 121: 441-449. PMID: 25403507, PMCID: PMC4323763, DOI: 10.1007/s11060-014-1658-0.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsMeSH KeywordsAnimalsAntineoplastic AgentsBrain NeoplasmsConvectionDrug Delivery SystemsFerric CompoundsGlioblastomaHumansImage Processing, Computer-AssistedLactic AcidMagnetic Resonance ImagingNanoparticlesNeuroimagingPolyglycolic AcidPolylactic Acid-Polyglycolic Acid CopolymerRatsRats, Sprague-DawleyConceptsBrain-penetrating nanoparticlesSuperparamagnetic iron oxideEfficient deliveryDrug-loaded nanoparticlesDistribution of nanoparticlesTransverse relaxivityPLGA nanoparticlesNanoparticlesConvection-enhanced deliveryDelivery platformFuture clinical applicationsUniversal tumor recurrenceClinical translationSignal attenuationDetection modalitiesIron oxideSame morphologyParticle distributionDeliveryGroundbreaking approachClinical applicationRelevant volumesRelaxivityTreatment of GBMOxide
2013
Highly penetrative, drug-loaded nanocarriers improve treatment of glioblastoma
Zhou J, Patel TR, Sirianni RW, Strohbehn G, Zheng MQ, Duong N, Schafbauer T, Huttner AJ, Huang Y, Carson RE, Zhang Y, Sullivan DJ, Piepmeier JM, Saltzman WM. Highly penetrative, drug-loaded nanocarriers improve treatment of glioblastoma. Proceedings Of The National Academy Of Sciences Of The United States Of America 2013, 110: 11751-11756. PMID: 23818631, PMCID: PMC3718184, DOI: 10.1073/pnas.1304504110.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and Concepts
Academic Achievements and Community Involvement
activity Member
CommitteesB*CURED FoundationDetails2008 - PresentDescriptionMedical Advisory Boardactivity Member
CommitteesAANSDetails2009 - PresentDescriptionEmerging Technology Committeehonor Connecticut Magazine Top Docs 2016
Regional AwardConnecticut MagazineDetails04/01/2016United Stateshonor Connecticut Magazine Top Docs 2015
Regional AwardConnecticut MagazineDetails04/03/2015United Statesactivity Member
CommitteesYNHHDetails2007 - 2010DescriptionSmilow Cancer Hospital Campaign
Links & Media
Media
News
- June 02, 2021
Yale Cancer Center and Smilow Cancer Hospital physicians recognized as Connecticut Magazine 'Best Doctors'
- December 07, 2020
Joseph Piepmeier, MD, to Retire After 44-Year Career
- June 04, 2020
Yale Cancer Center and Smilow Cancer Hospital physicians recognized as CT Magazine Best Doctors
- June 14, 2019
Over 200 Yale Medicine Physicians Make 2019 ‘Best Doctors’ List
Get In Touch
Contacts
Appointment Number
Clinic Fax Number
Mailing Address
Neurosurgery
PO Box 208082
New Haven, CT 06520-8082
United States